Literature DB >> 35445715

Association of insomnia and short sleep duration, alone or with comorbid obstructive sleep apnea, and the risk of chronic kidney disease.

Andrew E Beaudin1,2, Jill K Raneri3, Sofia Ahmed4,5, A J Hirsch Allen6, Andrhea Nocon7, Teresa Gomes8, Simon Gakwaya9, Frédéric Sériès9, John R Kimoff8, Robert Skomro7, Najib Ayas6, Patrick J Hanly2,3,4.   

Abstract

STUDY
OBJECTIVES: Obstructive sleep apnea (OSA), sleep fragmentation, and short sleep duration (SD) have been associated with chronic kidney disease (CKD). However, these potential mechanisms for CKD have not been compared in the same cohort. This study investigated the independent and combined impact of OSA and insomnia with short sleep duration on the risk of CKD progression in a sleep clinic population.
METHODS: In a cross-sectional study design, adults with suspected OSA completed an overnight sleep study and a questionnaire that included the Insomnia Severity Index (ISI) and Pittsburgh Sleep Quality Index (PSQI). They also provided blood and urine samples for measurement of the glomerular filtration rate and urine albumin:creatinine ratio, from which the risk of CKD progression was determined.
RESULTS: Participants (n = 732, 41% female, 55 ± 13 years) were categorized into four groups: no/mild OSA without insomnia (NM-OSA, n = 203), insomnia with SD without OSA (Insomnia-SD, n = 104), moderate-to-severe OSA without insomnia (MS-OSA, n = 242), and comorbid insomnia and OSA with SD (COMISA-SD, n = 183). After stratification, 12.8% of NM-OSA, 15.4% of Insomnia-SD, 28.9% of MS-OSA, and 31.7% of the COMISA-SD participants had an increased risk of CKD progression. Compared to NM-OSA, the odds ratio (OR) for an increased risk of CKD progression was not increased in Insomnia-SD (OR 0.95, confidence interval [CI]: 0.45-1.99) and was increased to the same degree in MS-OSA (OR 2.79, CI: 1.60-4.85) and COMISA-SD (OR 3.04, CI: 1.69-5.47). However, the ORs were similar between the MS-OSA and COMISA-SD groups across all statistical models (p ≥ .883).
CONCLUSIONS: In a sleep clinic population, insomnia with short sleep duration does not increase the risk of CKD progression; nor does it further increase the risk of CKD progression associated with moderate-to-severe OSA.
© The Author(s) 2022. Published by Oxford University Press on behalf of Sleep Research Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COMISA; chronic kidney disease; insomnia; obstructive sleep apnea; sleep duration

Mesh:

Year:  2022        PMID: 35445715      PMCID: PMC9272259          DOI: 10.1093/sleep/zsac088

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   6.313


  49 in total

Review 1.  Sleep disturbances as nontraditional risk factors for development and progression of CKD: review of the evidence.

Authors:  Nicolas F Turek; Ana C Ricardo; James P Lash
Journal:  Am J Kidney Dis       Date:  2012-06-21       Impact factor: 8.860

Review 2.  Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis.

Authors:  Adam V Benjafield; Najib T Ayas; Peter R Eastwood; Raphael Heinzer; Mary S M Ip; Mary J Morrell; Carlos M Nunez; Sanjay R Patel; Thomas Penzel; Jean-Louis Pépin; Paul E Peppard; Sanjeev Sinha; Sergio Tufik; Kate Valentine; Atul Malhotra
Journal:  Lancet Respir Med       Date:  2019-07-09       Impact factor: 30.700

3.  Cognitive and behavioral therapy for insomnia increases the use of continuous positive airway pressure therapy in obstructive sleep apnea participants with comorbid insomnia: a randomized clinical trial.

Authors:  Alexander Sweetman; Leon Lack; Peter G Catcheside; Nick A Antic; Simon Smith; Ching Li Chai-Coetzer; James Douglas; Amanda O'grady; Nicola Dunn; Jan Robinson; Denzil Paul; Paul Williamson; R Doug McEvoy
Journal:  Sleep       Date:  2019-12-24       Impact factor: 5.849

4.  Nocturnal hypoxemia severity influences the effect of CPAP therapy on renal renin-angiotensin-aldosterone system activity in humans with obstructive sleep apnea.

Authors:  David D M Nicholl; Patrick J Hanly; Ann A Zalucky; George B Handley; Darlene Y Sola; Sofia B Ahmed
Journal:  Sleep       Date:  2021-05-14       Impact factor: 5.849

5.  Comorbidity of chronic insomnia with medical problems.

Authors:  Daniel J Taylor; Laurel J Mallory; Kenneth L Lichstein; H Heith Durrence; Brant W Riedel; Andrew J Bush
Journal:  Sleep       Date:  2007-02       Impact factor: 5.849

6.  Objective short sleep duration is associated with the activity of the hypothalamic-pituitary-adrenal axis in insomnia.

Authors:  Carolina D'Aurea; Dalva Poyares; Ronaldo D Piovezan; Gisele Passos; Sergio Tufik; Marco Tulio de Mello
Journal:  Arq Neuropsiquiatr       Date:  2015-06       Impact factor: 1.420

7.  Sleep Duration and Quality in Relation to Autonomic Nervous System Measures: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Cecilia Castro-Diehl; Ana V Diez Roux; Susan Redline; Teresa Seeman; Paula McKinley; Richard Sloan; Steven Shea
Journal:  Sleep       Date:  2016-11-01       Impact factor: 5.849

Review 8.  Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics.

Authors:  Leon G Fine; Jill T Norman
Journal:  Kidney Int       Date:  2008-07-16       Impact factor: 10.612

9.  Nocturnal hypoxia and loss of kidney function.

Authors:  Sofia B Ahmed; Paul E Ronksley; Brenda R Hemmelgarn; Willis H Tsai; Braden J Manns; Marcello Tonelli; Scott W Klarenbach; Rick Chin; Fiona M Clement; Patrick J Hanly
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  A Reappraisal on the Associations between Sleep-disordered Breathing, Insomnia, and Cardiometabolic Risk.

Authors:  Miguel Meira E Cruz; Cristina Salles; David Gozal
Journal:  Am J Respir Crit Care Med       Date:  2021-06-15       Impact factor: 21.405

View more
  1 in total

Review 1.  More than sleepiness: prevalence and relevance of nonclassical symptoms of obstructive sleep apnea.

Authors:  Johan Verbraecken
Journal:  Curr Opin Pulm Med       Date:  2022-09-14       Impact factor: 2.868

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.